BRPI0014735B8 - composto 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metóxicarbonil-2-indolinona, seus sais e seu uso, bem como composição farmacêutica e seu processo de preparação. - Google Patents

composto 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metóxicarbonil-2-indolinona, seus sais e seu uso, bem como composição farmacêutica e seu processo de preparação.

Info

Publication number
BRPI0014735B8
BRPI0014735B8 BRPI0014735A BRPI0014735B8 BR PI0014735 B8 BRPI0014735 B8 BR PI0014735B8 BR PI0014735 A BRPI0014735 A BR PI0014735A BR PI0014735 B8 BRPI0014735 B8 BR PI0014735B8
Authority
BR
Brazil
Prior art keywords
methyl
indolinone
methylcarbonyl
anilino
piperazin
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
Armin Heckel
Gerald Juergen Roth
Rainer Walter
Meel Jacobus Van
Norbert Redemann
Ulrike Tontsch-Grunt
Walter Spevak
Frank Hilberg
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26006858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0014735(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19949208A external-priority patent/DE19949208A1/de
Priority claimed from DE2000142696 external-priority patent/DE10042696A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BRPI0014735A publication Critical patent/BRPI0014735A/pt
Publication of BRPI0014735B1 publication Critical patent/BRPI0014735B1/pt
Publication of BRPI0014735B8 publication Critical patent/BRPI0014735B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0014735 1999-10-13 2000-10-09 composto 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metóxicarbonil-2-indolinona, seus sais e seu uso, bem como composição farmacêutica e seu processo de preparação. BRPI0014735B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19949208A DE19949208A1 (de) 1999-10-13 1999-10-13 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE2000142696 DE10042696A1 (de) 2000-08-31 2000-08-31 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2000/009867 WO2001027081A1 (de) 1999-10-13 2000-10-09 In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel

Publications (3)

Publication Number Publication Date
BRPI0014735A BRPI0014735A (pt) 2002-07-16
BRPI0014735B1 BRPI0014735B1 (pt) 2012-07-10
BRPI0014735B8 true BRPI0014735B8 (pt) 2021-07-06

Family

ID=26006858

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0014735 BRPI0014735B8 (pt) 1999-10-13 2000-10-09 composto 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metóxicarbonil-2-indolinona, seus sais e seu uso, bem como composição farmacêutica e seu processo de preparação.

Country Status (43)

Country Link
EP (2) EP2157081A1 (OSRAM)
JP (2) JP4021664B2 (OSRAM)
KR (2) KR100835546B1 (OSRAM)
CN (1) CN100455568C (OSRAM)
AR (1) AR026036A1 (OSRAM)
AT (1) ATE439342T1 (OSRAM)
AU (1) AU781939B2 (OSRAM)
BE (1) BE2015C018I2 (OSRAM)
BG (1) BG65983B1 (OSRAM)
BR (1) BRPI0014735B8 (OSRAM)
CA (1) CA2387013C (OSRAM)
CO (1) CO5261488A1 (OSRAM)
CY (2) CY1110067T1 (OSRAM)
CZ (1) CZ301073B6 (OSRAM)
DE (1) DE50015711D1 (OSRAM)
DK (1) DK1224170T5 (OSRAM)
EA (1) EA006080B1 (OSRAM)
EE (1) EE05427B1 (OSRAM)
EG (1) EG25931A (OSRAM)
ES (1) ES2331459T3 (OSRAM)
FR (1) FR15C0024I2 (OSRAM)
HK (1) HK1052505B (OSRAM)
HR (1) HRP20020306B1 (OSRAM)
HU (2) HU230416B1 (OSRAM)
IL (2) IL148756A0 (OSRAM)
LT (1) LTC1224170I2 (OSRAM)
LU (1) LU92681I2 (OSRAM)
ME (1) MEP45408A (OSRAM)
MX (1) MXPA02002799A (OSRAM)
MY (1) MY127956A (OSRAM)
NL (1) NL300725I2 (OSRAM)
NO (3) NO322746B1 (OSRAM)
NZ (1) NZ518489A (OSRAM)
PE (1) PE20010671A1 (OSRAM)
PL (1) PL207445B1 (OSRAM)
PT (1) PT1224170E (OSRAM)
RS (1) RS51013B (OSRAM)
SA (1) SA01210704B1 (OSRAM)
SI (1) SI1224170T1 (OSRAM)
SK (1) SK287312B6 (OSRAM)
TW (1) TWI268922B (OSRAM)
UA (1) UA75054C2 (OSRAM)
WO (1) WO2001027081A1 (OSRAM)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
ATE419239T1 (de) 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
US6638965B2 (en) 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2003004007A2 (en) 2001-06-29 2003-01-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd)
US7727731B2 (en) 2001-06-29 2010-06-01 Ab Science Potent, selective and non toxic c-kit inhibitors
JP2004536097A (ja) * 2001-06-29 2004-12-02 アブ サイエンス 自己免疫疾患を治療するためのチロシンキナーゼ阻害剤の使用法
EP1401415B1 (en) 2001-06-29 2006-06-21 AB Science Use of n-phenyl-2-pyrimidine-amine derivatives for treating inflammatory diseases
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
US7700610B2 (en) 2001-06-29 2010-04-20 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
EP1430048A1 (en) * 2001-09-27 2004-06-23 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
MXPA04006271A (es) 2001-12-27 2004-10-04 Theravance Inc Derivados de indolinona utiles como inhibidores de la proteina cinasa.
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
ITBO20020198A1 (it) * 2002-04-12 2003-10-13 Univ Bologna Derivati 2 , 5 bis diammino 1 , 4 benzochenionici utili per il trattamento della malattia di alzheimer , metodo per la loro preparazione ed
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US7148249B2 (en) * 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
WO2008152013A1 (en) * 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh Indolinone derivatives and their use in treating disease-states such as cancer
ES2435454T3 (es) 2007-06-21 2013-12-19 Janssen Pharmaceutica, N.V. Indolin-2-onas y aza-indolin-2-onas
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
UY31506A1 (es) * 2007-12-03 2009-08-03 Derivados de indolinona y procedimiento para su preparacion
AR069530A1 (es) * 2007-12-03 2010-01-27 Boehringer Ingelheim Int Procedimiento para la fabricacion de un derivado de indolinona
KR101760657B1 (ko) 2008-06-06 2017-07-24 베링거 인겔하임 인터내셔날 게엠베하 약제학적 병용물
CN102112468A (zh) 2008-07-29 2011-06-29 贝林格尔.英格海姆国际有限公司 新化合物
US20120157472A1 (en) 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
EP2429520A1 (en) 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
KR101762999B1 (ko) 2011-04-18 2017-07-28 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료제
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
PL2807160T3 (pl) 2012-01-26 2020-03-31 Angion Biomedica Corp. Związki przeciwzwłóknieniowe i ich zastosowania
HK1214831A1 (zh) 2012-11-05 2016-08-05 Foundation Medicine, Inc. 新型融合分子及其应用
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
CN104936944B (zh) 2012-12-06 2017-09-12 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
EP2937337A4 (en) 2012-12-21 2016-06-22 Eisai R&D Man Co Ltd AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
EP2945652B1 (en) 2013-01-18 2021-07-07 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
WO2014185540A1 (en) 2013-05-14 2014-11-20 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (en) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
US20150044288A1 (en) 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
CN106660964B (zh) 2014-08-28 2021-09-03 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
CN104262232B (zh) * 2014-09-09 2016-05-04 苏州明锐医药科技有限公司 尼泰达尼的制备方法
IL253946B1 (en) 2015-02-25 2025-02-01 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivatives
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN104844499B (zh) * 2015-06-05 2017-03-08 北京康立生医药技术开发有限公司 一锅法制备尼达尼布的合成方法
MX393691B (es) * 2015-06-06 2025-03-24 Cloudbreak Therapeutics Llc Composiciones y metodos para tratar pterigion.
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN105126909B (zh) * 2015-07-13 2018-01-23 淮海工学院 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CZ308695B6 (cs) 2015-07-29 2021-03-03 Zentiva, K.S. Způsob přípravy methyl (Z)-3[[4-[methyl[2-(4-methyl-1piperazinyl)acetyl]amino]fenyl]amino]fenylmethylen)-oxindol-6karboxylátu (intedanibu, nintedanibu)
CN106467500A (zh) * 2015-08-14 2017-03-01 廊坊百瑞化工有限公司 一种一锅煮法合成尼达尼布关键中间体的新方法
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
PT3722291T (pt) 2015-12-24 2023-09-22 Respivert Ltd Compostos de indolinona e sua utilização no tratamento de doenças fibróticas
CZ2016104A3 (cs) 2016-02-24 2017-09-06 Zentiva, K.S. Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
CA3017308A1 (en) 2016-03-08 2017-09-14 Respivert Limited Indole derivatives and their use as protein kinase inhibitors
JP2019511547A (ja) 2016-04-13 2019-04-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 結腸直腸癌を治療するためのニンテダニブ、トリフルリジンおよびチピラシルの医薬組合せ
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
US20190275032A1 (en) 2016-05-27 2019-09-12 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for determining the treatment onset with nintedanib and pirfenidone
US20190275033A1 (en) 2016-06-01 2019-09-12 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for determining the treatment onset with nintedanib and pirfenidone
CN109561985B (zh) 2016-06-02 2022-03-04 拨云生物医药科技(广州)有限公司 使用尼达尼布改善青光眼手术成功情况的组合物和方法
WO2018022771A1 (en) 2016-07-29 2018-02-01 Oncternal Therapeutics, Inc. Uses of indolinone compounds
CN106748961A (zh) * 2016-11-30 2017-05-31 瑞阳制药有限公司 尼达尼布的杂质化合物、制备方法、应用及其检测方法
CN106748960A (zh) * 2016-11-30 2017-05-31 瑞阳制药有限公司 尼达尼布的潜在杂质化合物、制备方法、应用及其检测方法
EP3551187B1 (en) 2016-12-12 2021-02-17 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
EP3581183B1 (en) 2017-02-08 2023-11-29 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
WO2018177893A1 (en) 2017-03-28 2018-10-04 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of muscular dystrophy
KR20200013644A (ko) 2017-05-16 2020-02-07 에자이 알앤드디 매니지먼트 가부시키가이샤 간세포 암종의 치료
EP4603094A2 (en) 2017-10-23 2025-08-20 Boehringer Ingelheim International GmbH New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
EP3710427B1 (en) 2017-11-17 2023-03-08 Fermion Oy Synthesis of a 2-indolinone derivative known as intermediate for preparing nintedanib
JP7061310B2 (ja) * 2018-04-05 2022-04-28 国立大学法人 大分大学 慢性脂肪性疾患の予防および治療用医薬
CN108358827A (zh) * 2018-05-07 2018-08-03 日照市普达医药科技有限公司 一种治疗牛皮癣的2-氧代-吲哚类衍生物及其制备方法
KR20210013574A (ko) 2018-05-25 2021-02-04 클라우드브레이크 테라퓨틱스, 엘엘씨 안구 충혈 치료용 조성물 및 이를 사용하여 안구 충혈을 치료하는 방법
KR20210068479A (ko) * 2018-10-05 2021-06-09 아이크노스 사이언스 에스.에이. Map4k1 억제제로서의 사용을 위한 인돌리논 화합물
JP2023519600A (ja) 2020-04-01 2023-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維性状態の治療におけるバイオマーカーの使用
CN111848490B (zh) * 2020-08-24 2021-09-24 江西国药有限责任公司 一种高纯度乙磺酸尼达尼布的制备方法
CN112574094B (zh) * 2020-12-14 2022-07-01 成都大学 吲哚酮衍生物及其制药用途
US20240238368A1 (en) 2021-01-25 2024-07-18 Nibec Co., Ltd. Peptide for preventing and treating fibrosis
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
CN115703758B (zh) * 2021-08-12 2024-03-26 中国医学科学院药物研究所 一类用作激酶抑制剂的化合物及其制备方法和用途
EP4572763A1 (en) 2022-08-16 2025-06-25 Boehringer Ingelheim International GmbH Pharmaceutical formulations of nintedanib for intraocular use
TWI857798B (zh) * 2023-09-28 2024-10-01 國立臺灣大學 用於治療及/或預防腫瘤或細胞增生及纖維化疾病之吲哚啉衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE558210A (OSRAM) * 1956-06-08
CN1129400A (zh) * 1994-05-06 1996-08-21 阿尔康实验室公司 维生素e生育酚衍生物在眼科组合物中的应用
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CA2214759C (en) * 1996-01-17 2004-05-18 Taiho Pharmaceutical Co., Ltd. Intimal hypertrophy inhibitors
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19815020A1 (de) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19824922A1 (de) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
EP1224170A1 (de) 2002-07-24
CZ301073B6 (cs) 2009-10-29
WO2001027081A1 (de) 2001-04-19
BRPI0014735B1 (pt) 2012-07-10
IL148756A0 (en) 2002-09-12
CY2015009PI2 (el) 2016-12-14
JP4021664B2 (ja) 2007-12-12
PT1224170E (pt) 2009-10-01
KR100835546B1 (ko) 2008-06-09
HUP0204587A3 (en) 2004-07-28
CZ20021410A3 (cs) 2002-07-17
EA200200380A1 (ru) 2002-10-31
FR15C0024I2 (fr) 2016-08-26
HK1052505B (zh) 2009-06-26
CN1391557A (zh) 2003-01-15
MXPA02002799A (es) 2003-02-27
HK1052505A1 (en) 2003-09-19
DE50015711D1 (de) 2009-09-24
MEP45408A (en) 2011-02-10
NO322746B1 (no) 2006-12-04
KR100857734B1 (ko) 2008-09-10
NO2015009I2 (OSRAM) 2015-03-18
LTPA2015015I1 (lt) 2015-04-27
EP1224170B9 (de) 2017-11-22
KR20070095996A (ko) 2007-10-01
PL355433A1 (pl) 2004-04-19
BE2015C018I2 (OSRAM) 2019-10-23
EA006080B1 (ru) 2005-08-25
TWI268922B (en) 2006-12-21
BRPI0014735A (pt) 2002-07-16
NO2023033I1 (no) 2023-09-05
SA01210704B1 (ar) 2006-12-05
BG65983B1 (bg) 2010-08-31
AU781939B2 (en) 2005-06-23
EG25931A (en) 2012-10-24
NL300725I2 (nl) 2017-07-13
HUP0204587A2 (en) 2003-05-28
IL148756A (en) 2007-10-31
SK6462002A3 (en) 2002-08-06
PE20010671A1 (es) 2001-06-28
EP2157081A1 (de) 2010-02-24
MY127956A (en) 2007-01-31
AR026036A1 (es) 2002-12-26
LTC1224170I2 (lt) 2023-11-10
DK1224170T3 (da) 2009-12-07
NO2015009I1 (no) 2015-03-30
LU92681I9 (OSRAM) 2019-01-03
AU1023301A (en) 2001-04-23
CN100455568C (zh) 2009-01-28
CY2015009PI1 (el) 2016-12-14
JP2007302697A (ja) 2007-11-22
HRP20020306A2 (en) 2003-10-31
HRP20020306B1 (en) 2010-09-30
JP2003511441A (ja) 2003-03-25
FR15C0024I1 (OSRAM) 2015-04-17
EP1224170B1 (de) 2009-08-12
SK287312B6 (sk) 2010-06-07
BG106587A (bg) 2003-01-31
DK1224170T5 (en) 2018-01-22
CO5261488A1 (es) 2003-03-31
CA2387013C (en) 2009-12-29
HUS1600022I1 (hu) 2017-02-28
KR20020038949A (ko) 2002-05-24
NO20021719L (no) 2002-04-11
NZ518489A (en) 2005-05-27
EE05427B1 (et) 2011-06-15
YU26602A (sh) 2004-11-25
NO20021719D0 (no) 2002-04-11
PL207445B1 (pl) 2010-12-31
RS51013B (sr) 2010-10-31
LU92681I2 (fr) 2015-05-18
ATE439342T1 (de) 2009-08-15
CA2387013A1 (en) 2001-04-19
EE200200197A (et) 2003-06-16
HU230416B1 (hu) 2016-05-30
CY1110067T1 (el) 2015-01-14
ES2331459T3 (es) 2010-01-05
UA75054C2 (uk) 2006-03-15
SI1224170T1 (sl) 2009-12-31

Similar Documents

Publication Publication Date Title
BRPI0014735B8 (pt) composto 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metóxicarbonil-2-indolinona, seus sais e seu uso, bem como composição farmacêutica e seu processo de preparação.
BRPI0117360A2 (pt) inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
NO990551D0 (no) Piperidin- og piperazinderivater, og deres anvendelse som muskarine antagonister
DK1175401T3 (da) Piperazinderivater, der er nyttige som CCR5-antagonister
BRPI0408782A (pt) inibidores cìclicos da proteìna tirosina cinase
MEP53708A (en) 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl) -n-methyl -amino) -anilino)-1- phenyl-methylene] -6-methoxycarbonyl -2-indolinone -monoethanesulphonate and the use thereof as a pharmaceutical composition
EE05104B1 (et) Asetidiini derivaadid, nende valmistamise meetodid ja farmatseutiline kompositsioon
EE05405B1 (et) Kinaasi inhibiitoritena toimivad bitskloprasoolid, nende valmistamismeetod, kasutamine ja neid sisaldavad farmatseutilised kompositsioonid
EE200200647A (et) Farmatseutiliselt aktiivsed piperidiiniühendid, eriti kemokiiniretseptori aktiivsuse modulaatoritena
IS5983A (is) Píperidín, tetrahýdrópýridín og píperzín afleiður, framleiðsla þeirra og notkun
BRPI0212137A2 (pt) diidropteridinonas, processos para prepará-las e seu uso como composições farmacêuticas
NO20021450D0 (no) Cykliske aminforbindelser som CCR5 antagonister
BR0000908B1 (pt) derivados de 4-fenil-piridina, seu processo de preparação e seu uso, bem como medicamento que os contém
BR0015254B1 (pt) compostos derivados de carbamoiloxialquil-azàlio, seu uso, bem como composiÇço farmacÊutica compreendendo os mesmos.
DK1307457T3 (da) Azabicycliske forbindelser, deres fremstilling og deres anvendelse som medikamenter, især som antibakterielle midler
NO20002486L (no) Sykliske aminderivater og deres anvendelse som legemidler
DK1177178T3 (da) Heterocyclisk substituerede benzimidazoler, deres fremstilling og anvendelse
ATE283260T1 (de) 1-(1-subst.-4-piperidinyl)methyl)-4-piperidin- derivate, verafhren zu deren herstellung, pharmazeutische mixturen und intermediate zu deren herstellung
EE201000020A (et) Ravimkompositsioonid, mis p?hinevad antikolinergiliselt toimivatel henditel ja
DK1198453T5 (da) N-(indolcarbonyl-)piperazinderivater
EE200300327A (et) Uurea derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutiline kompositsioon
PT1445249E (pt) Novos derivados de benzofenona ou os seus sais
DK1185272T3 (da) Hidtil ukendt anvendelse af 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazin og dets fysiologisk acceptable salte til behandling af bipolære lidelser og mani
BR0008228A (pt) Composições de n-benzoil estaurosporinaespontaneamente dispersìveis
BRPI0012475B8 (pt) composto derivado de titânio, seu processo de preparação e utilização, bem como composição para uso oral compreendendo o mesmo.

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/07/2012, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/10/00, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.010583/2021-91 ORIGEM: 4A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 5025550-73.2019.4.02.5101 SUBJUDICE AUTOR: BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.010583/2021-91 NUP: 00424.177774/2021-80 (REF. 1074941-83.2021.4.01.3400) INTERESSADOS: BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG E OUTROS SENTENCA: DETERMINAR QUE A PATENTE PI0014735-4 ESTA VIGENTE POR 6 ANOS E 4 MESES (QUE CORRESPONDENTE A DEMORA DESPROPORCIONAL E INJUSTIFICADA DO INPI) ALEM DO ATUAL PRAZO DE VIGENCIA DESSA PATENTE COM FULCRO NO ARTIGO 40, CAPUT, DA LPI (ISTO E, 09.10.2020) ATE A CONCLUSAO DA PERICIA; E (II) OBRIGAR O INPI A PUBLICAR, NA REVISTA DE PROPRIEDADE INDUSTRIAL (RPI), ESSA DETERMINACAO, DEVENDO TAL INFORMACAO CONSTAR NO STATUS (PAGINA DE ANDAMENTO PROCESSUAL) DISPONIBILIZADO NO WEBSITE WWW.INPI.GOV.BR DA PATENTE EM QUESTAO, PARA FIN

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.000262/2022-69 NUP: 00424.000813/2022-32 (REF. 1045059-91.2021.4.01.0000) INTERESSADOS: SUN FARMACEUTICA DO BRASIL LTDA E OUTROS SENTENCA: A PATENTE PI0014735-4 ESTA VIGENTE POR 6 ANOS E 4 MESES (QUE CORRESPONDENTE A DEMORA DESPROPORCIONAL E INJUSTIFICADA DO INPI) ALEM DO ATUAL PRAZO DE VIGENCIA DESSA PATENTE COM FULCRO NO ARTIGO 40, CAPUT, DA LPI (ISTO E, 09.10.2020) ATE A CONCLUSAO DA PERICIA; E (II) OBRIGAR O INPI A PUBLICAR, NA REVISTA DE PROPRIEDADE INDUSTRIAL (RPI), ESSA DETERMINACAO, DEVENDO TAL INFORMACAO CONSTAR SEM STATUS (PAGINA DE ANDAMENTO PROCESSUAL) DISPONIBILIZADO NO SITE WWW.INPI.GOV.BR DA PATENTE EM QUESTAO, PARA FINS DE CONHECIMENTO POR PARTE DE

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.010583/2021-91 NUP: 00848.001050/2021-85 (REF. 00424.177774/2021-80) INTERESSADOS: BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG E OUTROS SENTENCA: CONSIDERANDO QUE HOUVE, ANTERIORMENTE A SENTENCA, O DEFERIMENTO DE MEDIDA LIMINAR/TUTELA ANTECIPADA NO CURSO DO PROCESSO, EXARO A DECLARACAO DE FORCA EXECUTORIA PARA DEIXAR CONSIGNADO QUE A DECISAO REFERIDA SEM EFICACIA